


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 23, 2002

Signature:


(Sharon M. Sintion)

RECEIVED
OCT 29 2002
1614
TECH CENTER 1600/2900

Docket No.: 28110/36858A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ford et al.

Application No.: 10/003,671

Group Art Unit: 1614

Filed: November 2, 2001

Projected Examiner: To be
determined

For: **NOVEL INTERLEUKIN-1 HY2
MATERIALS AND METHODS**

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Submitted herewith is a Form PTO-1449 listing several documents. Copies of documents B1-B2 and C1-C3 have been submitted in the parent application no. 09/316,081, filed May 20, 1999 and pursuant to 37 CFR §1.98(d), copies are not submitted herewith. Copies of documents C4-C6 are submitted herewith.

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 USC §102 or §103.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed to be due under 37 CFR §1.97 (b) because this statement and Form PTO-1449 are being submitted before receipt of a first office action on the merits in the above-identified patent application. However, the Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: October 23, 2002


Respectfully submitted,

By 
Sharon M. Sintich
Registration No.: 48,484
MARSHALL, GERSTEIN & BORUN
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agents for Applicant

Form PTO-1449 (Modified)

Atty. Docket No.
28110/36858ASerial No.
10/003,671

INFORMATION DISCLOSURE STATEMENT

Applicant(s)
Mize et al.Filing Date
November 2, 2001Art Unit
1614

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)
	RECEIVED					
	OCT 29 2002					
	TECH CENTER 1600/2900					

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No
B1	WO 98/347921	10/29/1998	WO		
B2	WO 99/51744	10/14/1999	WO		

OTHER DOCUMENTS

C1	Carter <i>et al.</i> , Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein, <i>Nature</i> 344: 633-638 (April 12, 1990).
C2	Genebank Accession No.: AC016724, <i>Homo sapiens</i> chromosome 2 clone RP11-339F22, Working Draft Sequence, 12 unordered pieces, deposited by Waterston, R.H., dated 07 July 2000.
C3	Genebank Accession No.: AQ766579, Human Genomic Sperm Library: deposited by Mahairas G.G. <i>et al.</i> , dated 30 July 1999.
C4	Boraschi <i>et al.</i> , Structure-Function Relationship in the IL-1 Family, <i>Frontiers in Bioscience</i> 1, d270-308, (October 1, 1995).
C5	Jensen <i>et al.</i> , IL-1 Signaling Cascade in Liver Cells and the Involvement of a Soluble Form of the IL-1 Receptor Accessory Protein ^{1,2} , <i>J. Immunol.</i> , 5277-5286 (2000).
C6	Vigers <i>et al.</i> , Crystal Structure of the Type-I Interleukin-1 Receptor Complexed With Interleukin-1 β , <i>Nature</i> 386: 190-194 (March 13, 1997).

EXAMINER:

DATE CONSIDERED: